inexpensive glp 1 Looking for more affordable GLP-1 options? Through manufacturer programs, eligible members may access GLP-1 medications, including Wegovy Oral, with pricing as low as $25 with insurance or $149 without.* Backed by pharmacist GLP-1 Drug Savings: A Complete

Patients should confirm current compounding status and medication availability directly with CareBareRX before enrolling

Get today's Zevay eligibility and pricing details Fast Facts Platform: Zevay, LLC - technology platform, not a medical practice or pharmacy Affiliated medical group named by the brand: Telegra MD (independent licensed physician network, per Zevay's site) Named pharmacy partners: Southend Pharmacy, Houston, TX

Tirzepatide has not been studied in pregnant or breastfeeding women, and animal studies suggest potential fetal harm

The side effect profiles are similar, and costs are comparable when considering available programs and compounded options

375 14.2 KEY STRATEGIES/RIGHT TO WIN 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET 14.3 REVENUE ANALYSIS, 20202024 14.4 MARKET SHARE ANALYSIS, 2024 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 14.6.5.1 COMPANY FOOTPRINT 14.6.5.2 REGION FOOTPRINT 14.6.5.3 FORMAT FOOTPRINT 14.6.5.4 ROUTE OF ADMINISTRATION FOOTPRINT 14.6.5.5 INDICATION FOOTPRINT 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 14.7.1 PROGRESSIVE COMPANIES 14.7.2 RESPONSIVE COMPANIES 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 14.7.5.1 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 14.8 COMPANY VALUATION & FINANCIAL METRICS 14.9 BRAND/PRODUCT COMPARISON 14.10 COMPETITIVE SCENARIO 14.10.1 PRODUCT APPROVALS 14.10.4 OTHER DEVELOPMENTS 15 COMPANY PROFILES In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View) 396 15.2.1.1 BUSINESS OVERVIEW 15.2.1.2 PRODUCTS OFFERED 15.2.1.3 RECENT DEVELOPMENTS 15.2.2 ELI LILLY AND COMPANY 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 15.2.8 SCIWIND BIOSCIENCES CO., LTD

66 Targeting multiple peptide hormone receptors with the same drug entity appears to be the most promising strategy, where additive, or even synergistic, benefits of simultaneously activating two receptor signalling pathways in bone can be fully realised